Ads
related to: federal patent lawsuit casescourtrec.com has been visited by 100K+ users in the past month
Search results
Results From The WOW.Com Content Network
This is a list of notable patent law cases in the United States in chronological order. The cases have been decided notably by the United States Supreme Court, the United States Court of Appeals for the Federal Circuit (CAFC) or the Board of Patent Appeals and Interferences (BPAI). While the Federal Circuit (CAFC) sits below the Supreme Court ...
Patent applicants who are unhappy with the final decision of the USPTO's Patent Trial and Appeal Board have two options to appeal: they can appeal to the Federal Circuit (which conducts a limited review of the Patent Trial and Appeal Board's decision) or sue the USPTO Director in the Eastern District of Virginia (which can consider new evidence ...
Akamai Technologies, Inc. v. Limelight Networks, Inc., 797 F.3d 1020 (Fed. Cir. 2015), [1] is a 2015 en banc decision of the United States Court of Appeals for the Federal Circuit, on remand from a 2014 decision of the U.S. Supreme Court reversing a previous Federal Circuit decision in the case.
A federal jury in Marshall, Texas, on Friday awarded computer memory company Netlist $118 million in damages from Samsung Electronics in a patent lawsuit over technology for improving data ...
(Reuters) -Apple convinced a federal jury on Friday that early versions of health monitoring tech company Masimo's smartwatches infringe two of its design patents as part of a broader intellectual ...
A Washington, D.C. federal court determined in a separate lawsuit in 2022 that the government breached research agreements with Gilead by applying for the patents without giving the company ...
In the specific case, Arthrex, Inc., a manufacturer of medical devices, had previously received a patent for a surgical device. They entered into a patent dispute with Smith & Nephew, Inc. and ArthroCare Corp., claiming the latter groups were infringing on their patent. The case moved into the PTAB, which found that Arthrex's patent was invalid.
Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), was a Supreme Court case, which decided that "a naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated.” [1] However, as a "bizarre conciliatory prize" the Court allowed patenting of complementary DNA, which contains exactly the same protein-coding ...